Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:CNTN NASDAQ:MREO NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.53-1.8%$2.77$0.97▼$3.60$182.38M0.32693,064 shs50,272 shsCNTNHillstream Biopharma$3.21+0.8%$3.43$1.08▼$9.08$182.50M1.44779,360 shs114,630 shsMREOMereo BioPharma Group$0.26+5.2%$0.33$0.20▼$3.05$40.70M0.246.58 million shs1.12 million shsTLSATiziana Life Sciences$1.50-2.0%$1.31$1.14▼$2.60$190.89M0.42188,882 shs29,050 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.39%+7.98%+4.05%+4.05%+162.22%CNTNHillstream Biopharma+5.63%-1.24%+7.05%+318,999,900.00%+318,999,900.00%MREOMereo BioPharma Group-2.84%-6.73%-26.29%-40.85%-89.94%TLSATiziana Life Sciences-3.16%+14.18%+29.66%+8.51%-0.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.53-1.8%$2.77$0.97▼$3.60$182.38M0.32693,064 shs50,272 shsCNTNHillstream Biopharma$3.21+0.8%$3.43$1.08▼$9.08$182.50M1.44779,360 shs114,630 shsMREOMereo BioPharma Group$0.26+5.2%$0.33$0.20▼$3.05$40.70M0.246.58 million shs1.12 million shsTLSATiziana Life Sciences$1.50-2.0%$1.31$1.14▼$2.60$190.89M0.42188,882 shs29,050 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+0.39%+7.98%+4.05%+4.05%+162.22%CNTNHillstream Biopharma+5.63%-1.24%+7.05%+318,999,900.00%+318,999,900.00%MREOMereo BioPharma Group-2.84%-6.73%-26.29%-40.85%-89.94%TLSATiziana Life Sciences-3.16%+14.18%+29.66%+8.51%-0.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.50Moderate Buy$6.67164.03% UpsideCNTNHillstream Biopharma 1.00SellN/AN/AMREOMereo BioPharma Group 2.25Hold$3.251,174.51% UpsideTLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MREO, ABOS, CNTN, and TLSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/8/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/23/2026MREOMereo BioPharma Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral3/19/2026MREOMereo BioPharma Group Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/16/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.003/9/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.16 per shareN/ACNTNHillstream BiopharmaN/AN/AN/AN/A$10.92 per shareN/AMREOMereo BioPharma Group$500K81.41N/AN/A$0.26 per share0.98TLSATiziana Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$2.01N/AN/AN/AN/A-111.26%-75.67%5/12/2026 (Estimated)CNTNHillstream Biopharma-$35.92M-$3.99N/AN/AN/AN/A-35.59%-27.05%N/AMREOMereo BioPharma Group-$41.88M-$0.06N/A25.50N/AN/A-83.02%-72.68%5/12/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A6/18/2026 (Estimated)Latest MREO, ABOS, CNTN, and TLSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028-$0.33+$0.0728-$0.33N/AN/A5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.05-$0.07-$0.05$11.67 millionN/A5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/A3/31/2026Q4 2025CNTNHillstream BiopharmaN/A$0.54N/A$0.54N/AN/A3/26/2026Q4 2025ABOSAcumen Pharmaceuticals-$0.50-$0.41+$0.09-$0.41N/AN/A3/20/2026Q4 2025MREOMereo BioPharma Group-$0.01-$0.01N/A-$0.05$5.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ACNTNHillstream BiopharmaN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.324.074.07CNTNHillstream BiopharmaN/A5.295.29MREOMereo BioPharma GroupN/A10.4710.46TLSATiziana Life SciencesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%CNTNHillstream Biopharma1.16%MREOMereo BioPharma Group62.83%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.10%CNTNHillstream Biopharma6.70%MREOMereo BioPharma Group6.50%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million67.10 millionOptionableCNTNHillstream Biopharma256.66 million52.86 millionN/AMREOMereo BioPharma Group40159.62 million149.24 millionOptionableTLSATiziana Life Sciences8127.26 million76.58 millionOptionableMREO, ABOS, CNTN, and TLSA HeadlinesRecent News About These CompaniesTiziana Life Sciences Delays Annual 20-F FilingMay 2, 2026 | theglobeandmail.comWall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to SellApril 18, 2026 | marketbeat.comTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and ...April 17, 2026 | finanznachrichten.deTiziana says intranasal drug shows potential to ease Long COVID “brain fog”April 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionApril 16, 2026 | globenewswire.comTiziana Life Sciences to present Phase 2a MSA study at World Parkinson CongressApril 14, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressApril 14, 2026 | globenewswire.comTiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingApril 1, 2026 | uk.finance.yahoo.comTiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain agingApril 1, 2026 | proactiveinvestors.comTiziana reports biomarker gains for nasal MS therapy in progressive diseaseFebruary 25, 2026 | proactiveinvestors.comTiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAFebruary 25, 2026 | globenewswire.comWhile insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownershipFebruary 9, 2026 | finance.yahoo.comTiziana Life Sciences publishes positive study on intranasal MS therapyJanuary 20, 2026 | proactiveinvestors.comTiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal ForalumabJanuary 20, 2026 | globenewswire.comTiziana Life Sciences announces closing of oversubscribed $8.8M offeringJanuary 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesJanuary 16, 2026 | globenewswire.comTiziana Life Sciences unveils registered direct offering of up to $17.6MJanuary 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 MillionJanuary 16, 2026 | globenewswire.comTiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San FranciscoJanuary 9, 2026 | globenewswire.comTiziana Life Sciences submits annual safety report for intranasal foralumab to FDADecember 29, 2025 | proactiveinvestors.comTiziana Files Annual Safety Report for Intranasal Foralumab with FDADecember 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMREO, ABOS, CNTN, and TLSA Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.52 -0.05 (-1.75%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Hillstream Biopharma NASDAQ:CNTN$3.21 +0.02 (+0.75%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.Mereo BioPharma Group NASDAQ:MREO$0.26 +0.01 (+5.15%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Tiziana Life Sciences NASDAQ:TLSA$1.50 -0.03 (-1.96%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
